American Journal of Cardiology
Volume 101, Issue 12 , Pages 1808-1809 , 15 June 2008

Controlled Rosuvastatin Multinational Trial in Heart Failure (The Positive Negative Trial)

Received 23 December 2007 ,Revised 2 February 2008 ,Accepted 2 February 2008.

References 

  1. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)). N Engl J Med. 1987;316:1429–1435
  3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  4. van Jaarsveld CH, Ranchor AV, Kempen GI, Coyne JC, van Veldhuisen DJ, Sanderman R. Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. Eur J Heart Fail. 2006;8:23–30
  5. Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, et al. Risk of thromboembolism in heart failure an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007;115:2637–2641
  6. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75
  7. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay J-F, et al. Statins inhibit platelet PAR-1 thrombin receptor in patients with metabolic syndrome: the PAR-1 Inhibition by Statins (PARIS) study. Am J Cardiol. 2006;97:1332–1336
  8. Serebruany VL, Malinin AI, Hennekens CH. Statins increase risk of haemorrhagic stroke by inhibition of PAR-1 receptor. Cerebrovasc Dis. 2007;24:477–479
  9. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413–418
  10. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, Fox CS, et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA. 2007;297:1455–1464
  11. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, Schønheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34:1080–1086
  12. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis. 2006;189:408–413
  13. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000;294:1043–1046
  14. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504

PII: S0002-9149(08)00385-8

doi: 10.1016/j.amjcard.2008.02.084

American Journal of Cardiology
Volume 101, Issue 12 , Pages 1808-1809 , 15 June 2008

Article Tools